Literature DB >> 31760437

Impact of preoperative duration of ulcerative colitis on long-term outcomes of restorative proctocolectomy.

Olga A Lavryk1, Luca Stocchi1, Tracy L Hull1, Jeremy M Lipman1, Sherief Shawki1, Stefan D Holubar1, Conor P Delaney1, Scott R Steele2.   

Abstract

BACKGROUND: It is unknown if ulcerative colitis (UC) duration has an impact on outcomes of ileal pouch anal anastomosis (IPAA). The aim of the study was to compare the long-term IPAA outcomes based on preoperative UC duration.
METHODS: All patients with pathologically confirmed UC who underwent IPAA were included from a prospectively maintained pouch database (1983-2017).Patient's cohort was stratified according to UC duration:< 5 years,5-10 years,10-20 years,> 20 years. UC duration was defined as time interval from date of preoperative diagnosis to colectomy date. The main outcome was Kaplan-Meier pouch survival. Secondary outcomes were pouch function and quality of life.
RESULTS: Out of 4502 IPAAs (1983-2016), 2797 patients were included. Treated with biologics versus 12% with UC duration > 20 years were 41% patients with UC duration < 5 years. Treated with steroids compared to shortest (34%,p < 0.001) were 54% patients with the longest disease. A total of 65% of patients with shortest disease had IPAAs performed mostly in 3 stages. Anastomotic separation and pelvic sepsis were more prevalent among shortest compared to longest disease groups. Rates of pouch-targeted fistulas, anastomotic strictures, and pouchitis were highest in longest disease group. Pouch survival was similar between groups. Multivariate analysis did not show a significant association between UC duration and pouch failure [1.05(0.97-1.1), p = 0.23].Longer UC duration was associated with increased odds of pouchitis [1.2(1.1, 1.3), p < 0.001]. Biologics agents were shown to be protective against pouchitis.
CONCLUSIONS: Preoperative UC duration does not increase pouch failure risk. Longer preoperative UC duration increases the pouchitis risk. Biologic agents and three-staged IPAA are protective against pouchitis and septic complications in long-term among patients with UC.

Entities:  

Keywords:  Disease duration; Ileal pouch anal anastomosis; Pouchitis; Ulcerative colitis

Mesh:

Year:  2019        PMID: 31760437     DOI: 10.1007/s00384-019-03449-1

Source DB:  PubMed          Journal:  Int J Colorectal Dis        ISSN: 0179-1958            Impact factor:   2.571


  16 in total

Review 1.  Risk factors and timing for colectomy in chronically active refractory ulcerative colitis: A systematic review.

Authors:  Fabio Salvatore Macaluso; Flaminia Cavallaro; Carla Felice; Marta Mazza; Alessandro Armuzzi; Paolo Gionchetti; Maurizio Vecchi; Ambrogio Orlando
Journal:  Dig Liver Dis       Date:  2019-02-06       Impact factor: 4.088

2.  An accelerated infliximab induction regimen reduces the need for early colectomy in patients with acute severe ulcerative colitis.

Authors:  David J Gibson; Zaid S Heetun; Ciaran E Redmond; Kavin S Nanda; Denise Keegan; Kathryn Byrne; Hugh E Mulcahy; Garret Cullen; Glen A Doherty
Journal:  Clin Gastroenterol Hepatol       Date:  2014-07-30       Impact factor: 11.382

3.  Restorative proctocolectomy: an example of how surgery evolves in response to paradigm shifts in care.

Authors:  F H Remzi; O A Lavryk; J H Ashburn; T L Hull; I C Lavery; D W Dietz; H Kessler; J M Church
Journal:  Colorectal Dis       Date:  2017-11       Impact factor: 3.788

4.  Ileal pouch anal anastomosis: analysis of outcome and quality of life in 3707 patients.

Authors:  Victor Warren Fazio; Ravi P Kiran; Feza H Remzi; John Calvin Coffey; Helen Mary Heneghan; Hasan Tarik Kirat; Elena Manilich; Bo Shen; Sean T Martin
Journal:  Ann Surg       Date:  2013-04       Impact factor: 12.969

5.  Predicting response after infliximab salvage in acute severe ulcerative colitis.

Authors:  Matthew C Choy; Dean Seah; Alexandra Gorelik; Yoon-Kyo An; Cheng-Yu Chen; Finlay A Macrae; Miles P Sparrow; William R Connell; Gregory T Moore; Graham Radford-Smith; Daniel R Van Langenberg; Peter De Cruz
Journal:  J Gastroenterol Hepatol       Date:  2018-02-27       Impact factor: 4.029

6.  Long-term functional outcome and quality of life after stapled restorative proctocolectomy.

Authors:  V W Fazio; M G O'Riordain; I C Lavery; J M Church; P Lau; S A Strong; T Hull
Journal:  Ann Surg       Date:  1999-10       Impact factor: 12.969

7.  The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients.

Authors:  Brian G Feagan; Walter Reinisch; Paul Rutgeerts; William J Sandborn; Songkai Yan; Debra Eisenberg; Mohan Bala; Jewel Johanns; Allan Olson; Stephen B Hanauer
Journal:  Am J Gastroenterol       Date:  2007-02-23       Impact factor: 10.864

8.  Prospective, age-related analysis of surgical results, functional outcome, and quality of life after ileal pouch-anal anastomosis.

Authors:  Conor P Delaney; Victor W Fazio; Feza H Remzi; Jeff Hammel; James M Church; Tracy L Hull; Anthony J Senagore; Scott A Strong; Ian C Lavery
Journal:  Ann Surg       Date:  2003-08       Impact factor: 12.969

9.  Timing of surgery in ulcerative colitis in the biologic therapy era-the patient's perspective.

Authors:  Jörn Gröne; Eva-Maria Lorenz; Claudia Seifarth; Hendrik Seeliger; Martin E Kreis; Mario H Mueller
Journal:  Int J Colorectal Dis       Date:  2018-07-12       Impact factor: 2.571

10.  Delayed surgery for acute severe colitis is associated with increased risk of postoperative complications.

Authors:  J Randall; B Singh; B F Warren; S P L Travis; N J Mortensen; B D George
Journal:  Br J Surg       Date:  2010-03       Impact factor: 6.939

View more
  2 in total

Review 1.  Staging Pouch Surgery in Ulcerative Colitis in the Biological Era.

Authors:  Anton Risto; Maie Abdalla; Pär Myrelid
Journal:  Clin Colon Rectal Surg       Date:  2022-01-17

2.  Prevalence of 'pouch failure' of the ileoanal pouch in ulcerative colitis: a systematic review and meta-analysis.

Authors:  Zaid Alsafi; Alice Snell; Jonathan P Segal
Journal:  Int J Colorectal Dis       Date:  2021-11-26       Impact factor: 2.571

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.